![]() | |
Abbreviation | NIPRD |
---|---|
Founded | 1987 |
Headquarters | Abuja, FCT, Nigeria |
Coordinates | 9°02′51″N7°20′29″E / 9.0475°N 7.3415°E |
Official language | English |
Director General | Obi Peter Adigwe |
Parent organization | Federal Ministry of Health |
Website | https://www.niprd.gov.ng |
![]() | This article is actively undergoing a major edit for a little while. To help avoid edit conflicts, please do not edit this page while this message is displayed. This message was added at 10:30, 9 July 2025 (UTC). This page was last edited at 12:02, 9 July 2025 (UTC) (3 seconds ago) – this estimate is cached, . Please remove this template if this page hasn't been edited for a significant time. If you are the editor who added this template, please be sure to remove it or replace it with {{ Under construction }} between editing sessions. |
The National Institute for Pharmaceutical Research and Development (NIPRD) is a Nigerian institution charged with developing drugs, biological products, and pharmaceutical raw materials, conducting quality-assurance tests, research for locally manufactured medicines, and constituting guidelines for their production. [1] [2] Founded in 1987, it was a parastatal under the Federal Ministry of Science and Technology. In 2001, it was moved to Federal Ministry of Health. [3] [1]
The NIPRD produces Niprisan for the management of sickle cell disorders. It is commercialized as Niclovix. [9] Niprisan is a phytochemical formulated from parts of four different indigenous plants ( Piper guineense seeds, Pterocarpusosun stem, Eugenia caryophyllus fruit and Sorghum bicolor leaves). In June 2018, May & Baker signed a production agreement with NIPRD for the commercialization of Niprisan in Nigeria. [10]
In July 2022, The Director-General of NIPRD, Dr. Obi Peter Adigwe, announced that more than 40 countries buy Niprisan from Nigeria. [11] [12]
In March 2020, under the directive of the Federal Government, the NIPRD started developing models to identify herbal medicines to combat COVID-19. [13] By early 2021, NIPRD had discovered Niprimune, a locally made phytomedicine as an adjunct for the management of COVID-19 [14] and was approved by the National Agency for Food and Drug Administration and Control (NAFDAC). [15] The Institute had decried lack of funding to advance its production and further research. [16] [17]